Plasmid-Encoded BoNT/A3 and A4 Neurotoxin Genes
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current methods for obtaining and purifying botulinum neurotoxin (BoNT) subtypes, particularly BoNT/A3 and BoNT/A4, face challenges due to varying quantities produced by different strains, leading to complications in therapeutic and research applications, and existing BoNT/A1-based pharmaceuticals become immunogenic upon repeated use.
Innovation Solution
Isolation and characterization of native plasmids from Clostridium botulinum type A strains that encode BoNT/A3 and BoNT/A4, allowing for the production of non-neutralized BoNT/A subtype complexes suitable for therapeutic and research purposes, including the use of plasmids pCLK and pCLJ which encode the respective neurotoxin genes and associated protein complexes.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If BoNT/A1-based pharmaceuticals are used for repeated treatment, then therapeutic efficacy is achieved, but immunogenicity increases leading to antibody neutralization and treatment resistance
Solution Approach 1:
The patent segments the BoNT/A serotype into distinct subtypes (A1, A2, A3, A4) based on genetic variations in the cntA gene. By isolating and characterizing plasmid-encoded BoNT/A3 and BoNT/A4 subtypes, the invention provides alternative therapeutic agents that are genetically distinct from BoNT/A1, thereby avoiding antibody cross-neutralization while maintaining therapeutic efficacy.
2Adaptability or versatility
If different C. botulinum strains are used to produce BoNT subtypes, then diverse neurotoxin variants are obtained, but production quantity varies significantly complicating purification
Solution Approach 1:
The patent extracts and isolates the cntA gene encoding BoNT/A3 or BoNT/A4 from native plasmids of C. botulinum type A strains. By transferring these specific genes into a suitable expression host system, the invention enables controlled, high-yield production of the desired neurotoxin subtypes, overcoming the low and variable production quantities observed in natural strains.
Solution Approach 2:
The patent uses plasmid vectors as intermediaries to carry the cntA gene from native C. botulinum strains into expression hosts. These plasmids serve as mediators that enable efficient gene transfer and expression, facilitating large-scale production of BoNT/A subtypes while maintaining genetic authenticity.
3Stability of the object's composition
If neurotoxin gene clusters are located on chromosome or bacteriophages, then stable inheritance is achieved, but genetic manipulation and plasmid isolation are limited
Solution Approach 1:
The patent extracts the cntA gene from its native chromosomal or phage-associated location and relocates it to an isolated plasmid vector. This extraction enables independent manipulation of the neurotoxin gene, facilitating genetic engineering, expression optimization, and efficient production without the constraints of chromosomal integration.
Solution Approach 2:
The patent transforms the static, fixed location of neurotoxin genes in the chromosome or bacteriophages into a dynamic, movable plasmid-based system. This allows flexible genetic manipulation, including gene insertion, deletion, and expression control, while maintaining stable inheritance through plasmid replication and segregation.
Data Source
AI summary
The present invention provides a novel isolated plasmid, wherein the plasmid is a native plasmid found in unique C. botulinum type A strains and encode either BoNT/A3 or BoNT/A4 and BoNT/B. The present invention also provides a method of obtaining a plasmid-encoded botulinum neurotoxin and botulinum neurotoxin complex comprising the step of isolating a plasmid encoding the cntA/A or cntA/B neurotoxin gene and genes encoding protein components of the toxin complex from a C. botulinum type A strain. The inventors performed comparative analyses of representative BoNT/A subtype strains by pulsed-field gel electrophoresis (PFGE) and Southern hybridizations with probes specific for the BoNT/A and B genes, cntA/A and cntA/B. Unexpectedly, the inventors determined that the genes encoding BoNT/A3 in the A3 strain, and BoNT/A4 and BoNT/B in the A4 strain, are on plasmids.